Probiotic products have moved to the forefront of health and nutrition, supported by growing evidence that healthy microbiome strengthens overall wellness. This has pushed pharmaceutical and nutraceutical companies to expand into probiotics as a core category. Traditional probiotic capsules, however, often break down too late in the digestive process, which can limit how much of the probiotics remain active and potentially compromise the impact for consumers. This is where Wandler Probiotics has emerged as a leading pioneer. Based in Canada, the company focuses on creating high-quality liquid probiotic products that aim to transform both human and animal health. Founded by Niels Wandler, Wandler Probiotics has grown from a concept into a well-established player in the industry, with a unique approach that emphasizes fermentation science and the benefits of liquid probiotics. The company’s leadership, under the guidance of Lars Wandler, president, has taken this innovative approach to the next level. With a passion for improving health and wellness, they have propelled the company to new heights. Together, they have refined the production of liquid probiotics, ensuring their products meet the highest standards of quality and deliver tangible health benefits to consumers. A Unique Focus on Liquid Probiotics The core philosophy of Wandler Probiotics is based on the belief that probiotics should be consumed in liquid form rather than as pills or powders. This idea stems from a deep understanding of how the body interacts with microorganisms. According to Lars, the efficacy of liquid probiotics comes from their ability to begin interacting with the body immediately upon consumption.
Life Science Consulting
Successful drug development in today’s fast-paced Life Sciences industry goes beyond just meeting regulatory requirements. It calls for agile strategies, efficient team structures, and a proactive approach across every stage, from early clinical planning to the final commercial rollout. To keep pace, companies need a partner who can navigate scientific and operational complexities. Demberg PharmaSolutions (DPS) has evolved into that partner. Once primarily known for its strength in quality systems and regulatory guidance, the firm now delivers full-spectrum consulting across the entire product lifecycle. With over 35 years of experience in the life sciences and regulatory environment, founder and president Natasha Demberg leads DPS in helping pharmaceutical, biotech, cosmetic, and healthcare organizations streamline operations and maintain compliance across all stages of product lifecycle starting at early development stage, such as Phase 1 clinical study. DPS guides their partners from early-stage clinical trials through to commercialization, process alignment, and strategic organizational design, adopted to every step. Whether managing global trials or restructuring internal workflows, DPS ensures that science, strategy, and operational structure are fully aligned, driving sustainable success in an increasingly complex development landscape. It has built flexible quality systems that support clinical trials from the outset, allowing for a smooth progression into commercialization without the burden of costly system changes. This approach saves time and resources, setting a strong foundation for long-term success. “Our goal is not just to meet the standard but to help clients build systems and teams that are scalable and future-ready,” says Demberg. By embedding compliance with key regulatory GxP standards, including FDA, EMA, and Health Canada, into its processes, DPS helps clients stay ahead of regulatory demands while advancing their growth goals. Its quality support evolves with each stage of development, from early-phase trials to post-market surveillance, ensuring a tailored, phase-specific approach at every step..
Life Science Consulting
Plum Clinical Solutions is a boutique consultancy helping early-stage and growing biotech companies navigate clinical supply management’s intricate operational, regulatory, and technical demands. The firm specializes in forecasting and planning of clinical supplies, manufacturing and labeling of clinical supplies, setup of the IRT and inventory management, global logistics and distribution, and specialty areas such as logistics for ultra-cold chain or controlled substances, offering comprehensive, hands-on support across the entire clinical supply lifecycle. Clare Plumtree, founder and principal consultant at Plum Clinical Solutions, is at the heart of the consultancy. A pharmaceutical industry veteran with over 25 years of experience, she has focused on clinical supplies for the past 15 years. After her previous company was acquired and the team was let go, Plumtree transitioned into consultancy and identified a crucial market gap. Small and mid-sized biotech firms often struggle to meet rising clinical supply demands because they lack the necessary infrastructure and headcount. “I often come in when complexity is growing faster than headcount,” says Plumtree. “Many smaller companies try to manage supply responsibilities by distributing them across project managers or CMC leads, but as the study scales, that approach quickly becomes unmanageable.” Flexible, Embedded Clinical Supply Leadership Having worked across multiple organizations and study phases, she founded Plum Clinical Solutions to fill a growing need for hands-on, technical supply leadership in smaller, fast-moving biotech environments. Plumtree works directly with clients as a fractional FTE or embedded consultant, providing the dual advantage of strategic oversight and hands-on execution. Each engagement begins with a scoping discussion to assess needs, define deliverables, and agree on the working model, hourly or retainer, ensuring alignment before work begins. Her cross-functional background in clinical operations, CMC, and logistics enables seamless coordination between internal teams and external vendors. The model is built on flexibility, accountability, and deep subject-matter expertise, offering biotech organizations a single, experienced point of contact throughout each engagement..
Life Science Consulting
The Role of Patient Reported Outcomes to Support Reimbursement and Market Access in Major European Countries and the US
Lothar Tremmel, Vice President, QCSR (Biometrics + Epidemiology), CSL Behring
Life Science Consulting
Cannabis and Biotech: Today and Tomorrow
Ivan A. Salazar, Plant Packaging & Sanitation Manager, Organigram
Supplements
Changes in Healthcare Leadership: Progress and Areas for Improvement
Tylar Chappell-Johnson, Physical Therapy Outpatient Clinic Manager, Luminis Health
Life Science Financial Services
Stat Testing: Rapid Results, Reliable Care
Anastasia Pinkston, HTL (ASCP), M. Ed., Manager Anatomic Pathology, and Maria Lurleen B. Codoy, MS, Molecular Microbiology Technical Specialist, the George Washington University Hospital
Life Science Consulting
Enhancing HCP Engagement by Evolving our Medical DNA
Sébastien Michaud, Vice President, Medical Strategy Oncology & Neurology / Immunology, North America Medical Affairs, EMD Serono, Inc
IN MY OPINION
Supplements
Making Cell Therapy Accessible to All Patients
Nuala Trainor, Director of Innovation, Lonza [SWX: LONN]
LAST WORD
Supplements
Turning Insights into Impact: How Life Sciences Companies Can Navigate Today's Complexities
Denise Juliano, Group VP of Life Sciences, Premier Inc. [NASDAQ: PINC]
IN FOCUS
Integrated Life Sciences Consulting in Canada's Clinical Trial Ecosystem
Canadian clinical trials face regulatory and logistical challenges; integrated consulting uses analytics, AI, and rigorous microbial controls to optimize supply chains, ensure compliance, and deliver safe, timely treatments.
Canada's Genomic-First Revolution: Transforming Microbial Diagnostics, Surveillance, and Personalized Medicine
Canada leads in integrating microbial genomics into healthcare, using next-generation sequencing for rapid diagnostics, surveillance, and personalized medicine, enhancing public health and precision treatment nationwide.
EDITORIAL
Biotech Insights Strengthening Life Sciences Outcomes
The focus here is on the leaders delivering excellence across microbial solutions, clinical supplies consultancy and life sciences consulting in Canada. The featured organizations show how specialized expertise and thoughtful execution drive dependable research outcomes and sustainable progress across the life sciences ecosystem. Together, these perspectives reflect a life sciences environment defined by capability, credibility and long-term value.
In this edition of Life Sciences Review Canada, the focus is on scientific innovation shaping microbial solutions, clinical supply excellence and life sciences consulting. The coverage highlights how research-driven expertise and strategic execution are strengthening development pathways, operational reliability and long-term value across Canada’s life sciences ecosystem.
The cover features Wandler Probiotics Inc. a Canada-based innovator in liquid fermentation science. The company develops tailored probiotic solutions for human, animal, and agricultural health, delivering immediate efficacy, improved microbial balance and measurable wellness outcomes through advanced liquid probiotic technology.
This feature also highlights leaders advancing life sciences and biotechnology through innovation and applied insight. Ivan A. Salazar, Plant Packaging & Sanitation Manager at Organigram, examines how biotechnology, data-driven cultivation and process optimization are shaping cannabis commercialization and research. Continuing this perspective, Denise Juliano, group vice president of life sciences at Premier Inc., highlights how real-world data, analytics and collaboration help life sciences organizations accelerate trials and drive meaningful healthcare outcomes.
We hope this coverage inspires fresh thinking about the future of life sciences and biotechnology in Canada and beyond as it spotlights the advancements that are setting the stage for more precise, scalable and patient-centered healthcare solutions.


